Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications

被引：0

作者：

Busset, M. Droz Dit ^{[1
]}

Braun, S. ^{[2
]}

El-Rayes, B. ^{[3
]}

Harris, W. P. ^{[4
]}

Damjanov, N. ^{[5
]}

Masi, G. ^{[6
]}

Rimassa, L. ^{[7
]}

Bhoori, S. ^{[8
]}

Niger, M. ^{[9
]}

Personeni, N. ^{[10
]}

Braiteh, F. ^{[11
]}

Lonardi, S. ^{[12
]}

Engelhardt, M. ^{[2
]}

Saulay, M. ^{[2
]}

Schwartz, B. ^{[13
]}

Shaib, W. L. ^{[14
]}

Mazzaferro, V. ^{[15
]}

Papadopoulos, K. P. ^{[16
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Dept Surg & Oncol, Milan, Italy

[2] Basilea Pharmaceut AG, Dev, Basel, Switzerland

[3] Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA

[4] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA

[5] Abramson Canc Ctr, VA Med Ctr, Sect Chief Hematol Oncol, Philadelphia, PA USA

[6] Azienda Osped Univ S Chiara, Oncol, Pisa, Italy

[7] Ist Clin Humanitas, Humanitas Canc Ctr, Rozzano, Italy

[8] Fdn IRCCS Ist Nazl Tumori, Sc Med Nucl, Milan, Italy

[9] Ist Nazl Tumori Milano Fdn IRCCS, Oncol, Milan, Italy

[10] Ist Clin Humanitas, Oncol, Rozzano, Italy

[11] Comprehens Canc Ctr Nevada, Oncol, Las Vegas, NV USA

[12] Ist Oncol Veneto IRCCS, Med Oncol Unit 1, Padua, Italy

[13] ArQule Inc, Burlington, MA USA

[14] Emory Univ, Hematol & Oncol, Atlanta, GA 30322 USA

[15] Fdn IRCCS Ist Nazl Tumori, Oncol, Milan, Italy

[16] START, Clin Res, San Antonio, TX USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

721P

引用

页数：2

共 50 条

[1] Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications
Borad, M.
Javle, M.
Shaib, W. L.
Mody, K.
Bergamo, F.
Harris, W. P.
Damjanov, N.
Macarulla, T.
Brandi, G.
Masi, G.
Busset, M. Droz Dit
Boncompagni, A.
Dimova-Dobreva, M.
Engelhardt, M.
Saulay, M.
Halfdanarson, T. R.
Knox, J.
Abou-Alfa, G. K.
Personeni, N.
Mazzaferro, V.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S567 - S568
[2] Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA).
Busset, Michele Droz Dit
El-Rayes, Bassel F.
Harris, William Proctor
Damjanov, Nevena
Masi, Gianluca
Rimassa, Lorenza
Bhoori, Sherrie
Niger, Monica
Personeni, Nicola
Braiteh, Fadi S.
Lonardi, Sara
Braun, Stephan
Engelhardt, Marc
Saulay, Mikael
Schwartz, Brian E.
Kazakin, Julia
Shaib, Walid Labib
Mazzaferro, Vincenzo
Papadopoulos, Kyriakos P.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3] FIDES-01, a phase II study of derazantinib in patients with unresectable intrahepatic cholangiocarcinoma (iCCA) and FGFR2 fusions and mutations or amplifications (M/A)
Javle, Milind M.
Shaib, Walid Labib
Braun, Stephan
Engelhardt, Marc
Borad, Mitesh J.
Abou-Alfa, Ghassan K.
Boncompagni, Andrea
Friedmann, Silke
Gahlemann, Christoph Georg
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[4] Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Pooled analysis of clinical trials and early access programs
Busset, M. Droz Dit
Shaib, W. L.
Harris, W. P.
Damjanov, N.
Borad, M.
Vogel, A.
Bridgewater, J. A.
Sellmann, L.
Dadduzio, V.
Borner, M.
Snider, J.
Cantero, F.
Saulay, M.
Braun, S.
Mazzaferro, V.
Javle, M.
ANNALS OF ONCOLOGY, 2020, 31 : S1231 - S1231
[5] Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01
Javle, Milind M.
Abou-Alfa, Ghassan K.
Macarulla, Teresa
Personeni, Nicola
Adeva, Jorge
Bergamo, Francesca
Malka, David
Vogel, Arndt
Knox, Jennifer J.
Evans, T. R. Jeffry
Dimova-Dobreva, Miryana
Harris, William Proctor
Saulay, Mikael
Engelhardt, Marc
Braun, Stephan
Busset, Michele Droz Dit
Borad, Mitesh J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[6] FGFR2 fusion in resectable intrahepatic cholangiocarcinoma patients
Xu, S.
Zheng, Y.
Gong, W.
Li, B.
Wang, Y.
Li, H.
Zhao, S.
Shi, X.
Zhang, L.
ANNALS OF ONCOLOGY, 2020, 31 : S267 - S267
[7] Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Mazzaferro, Vincenzo
El-Rayes, Bassel F.
Busset, Michele Droz Dit
Cotsoglou, Christian
Harris, William P.
Damjanov, Nevena
Masi, Gianluca
Rimassa, Lorenza
Personeni, Nicola
Braiteh, Fadi
Zagonel, Vittorina
Papadopoulos, Kyriakos P.
Hall, Terence
Wang, Yunxia
Schwartz, Brian
Kazakin, Julia
Bhoori, Sherrie
de Braud, Filippo
Shaib, Walid L.
BRITISH JOURNAL OF CANCER, 2019, 120 (02) : 165 - 171
[8] Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro
Bassel F. El-Rayes
Michele Droz dit Busset
Christian Cotsoglou
William P. Harris
Nevena Damjanov
Gianluca Masi
Lorenza Rimassa
Nicola Personeni
Fadi Braiteh
Vittorina Zagonel
Kyriakos P. Papadopoulos
Terence Hall
Yunxia Wang
Brian Schwartz
Julia Kazakin
Sherrie Bhoori
Filippo de Braud
Walid L. Shaib
British Journal of Cancer, 2019, 120 : 165 - 171
[9] FGFR2 fusion and/or rearrangement profiling in Chinese patients with intrahepatic cholangiocarcinoma
Huang, X-W.
Shi, G-M.
Zhang, T.
Bao, L-Q.
Wen, T-F.
Zhang, B.
Peng, T.
Zhao, H.
Kuang, M.
Wang, W-L.
Ran, J-H.
Liu, Y-B.
Gong, W.
Mou, H-B.
Luo, Y.
Wang, Y.
Sun, H.
Fan, J.
Liu, L-X.
Dai, M.
ANNALS OF ONCOLOGY, 2021, 32 : S379 - S379
[10] Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma
Krook, Melanie A.
Lenyo, Alexandria M.
Wilberding, Maxwell J.
Barker, Hannah D.
Dantuono, Mikayla
Chen, Hui-Zi
Reeser, Julie W.
Wing, Michele R.
Miya, Jharna
Samorodnitsky, Eric
Smith, Amy M.
Dao, Thuy
Martin, Dorrelyn M.
Dittmar, Kristin
Ciombor, Kristen K.
Hays, John L.
Freud, Aharon G.
Roychowdhury, Sameek
CANCER RESEARCH, 2019, 79 (13)

← 1 2 3 4 5 →